health
'Game-changer' GLP-1s could fix America's obesity crisis—but 2 inequalities stand in the way
For roughly 40% of American adults living with obesity, the medical playbook has barely changed in decades: Eat less, move more, and if that fails, wait until the disease progresses far enough to justify surgery. GLP-1 drugs like Ozempic, Wegovy, and Zepbound have broken that script—but according to Robin Wenzel, head of Wells Fargo Industry Insights, the drugs are exposing a harder problem than obesity itself: who can afford to wait for them to work.
TL;DR
- GLP-1 drugs represent a paradigm shift in obesity treatment, moving from late-stage interventions to proactive weight management.
- These drugs have shown significant reductions in cardiovascular events and are being linked to decreased substance abuse.
- The high cost of GLP-1s is a major obstacle, creating an affordability gap and raising concerns about equitable access.
- The long-term nature of benefits from GLP-1s creates a 'patience tax,' exacerbating inequalities for those who cannot afford sustained treatment.
- While price reductions and temporary coverage solutions are being implemented, issues of cost and access remain complex and fragmented.
- Patent expirations and market competition are expected to influence pricing and accessibility in the coming years.